Why China's pharmaceutical stocks rose
China's pharmaceutical stocks rose for the following reasons:
1. The company itself has a number of product varieties, and the company has been expanding the new product line, focusing on anti-tumor, cardiovascular and cerebral vascular, while the layout of the vaccine industry, so that the categories can be continued to expand.
2. Currently, the company is in a multi-category high-speed development period, and in the expansion of new strategic product layout has made progress in the stage, is about to open the vaccine industry's strategic products, which has a lot of imagination.
3. The company is in the process of reaching an agreement with 118 customers around the world to obtain the rights and interests of API products and distribution licenses, and has determined that the equity income of the pharmaceuticals in the next two years totaled 1.474 billion euros, which will provide security for the company's performance.
4. The company is located in the pharmaceutical industry has good prospects for development, the pharmaceutical industry is in a period of rapid development, the industry concentration trend is obvious.
The above information is for reference only, investment risk, please be careful when entering the market.
China's pharmaceutical stock investment
China's pharmaceutical stock investment has the following:
1. The pharmaceutical industry in the national economy of the various sectors of the development of the relatively fast, the pharmaceutical industry in the next few years will still maintain a stable growth trend.
2. The overall operation of the pharmaceutical industry is good, the next few years will be a period of rapid development of the pharmaceutical industry.
3. The pharmaceutical industry has a high rate of return on investment, which is more attractive to capital.
4. The pharmaceutical industry has a high growth potential and investment value, worth investors' attention and participation.
The above information is for reference only, the stock market is risky, investment should be cautious.
China's pharmaceutical stock investment lessons
China's pharmaceutical stock investment lessons are as follows:
1. Before the epidemic, the appropriate layout of high-quality pharmaceutical companies. After the epidemic, the pharmaceutical sector also experienced a wave of overheated rise, which should be properly withdrawn to avoid risk.
2. usually pay more attention to the national pharmaceutical policy. National policy on the pharmaceutical industry often change, policy changes on the pharmaceutical industry has a great impact on the pharmaceutical company's business situation.
3. During the epidemic, proper attention should be paid to pharmaceutical stocks. During the epidemic, pharmaceutical stocks benefited to a certain extent due to the oversupply of supplies such as masks and protective clothing. This opportunity is short-term and investors should exit in time to avoid risk.
4. Insist on long-term investment. Pharmaceutical industry as a long bull industry, has a broad development prospects, investors in the investment of pharmaceutical stocks, should be based on long-term investment, to avoid short-term behavior.
5. Focus on pharmaceutical R&D innovation. The pharmaceutical industry is very competitive, pharmaceutical companies to maintain market competitiveness, must strengthen the R & D innovation, investors in the choice of pharmaceutical stocks, should pay attention to the company's R & D innovation capabilities.
6. Focus on the fundamentals of the pharmaceutical company. When investing in stocks, you should pay attention to the fundamentals of the pharmaceutical company, such as financial status, market competitiveness, product R & D capability, etc., to avoid blindly following the trend.
7. Be alert to risk. Pharmaceutical stock prices fluctuate greatly, investors should pay attention to risk when investing to avoid losses.
China Pharmaceuticals Stock Tailgate Buy
China Pharmaceuticals Stock Tailgate Buy may have the following reasons:
1. The general market condition: China Pharmaceuticals Stock Tailgate Buy is due to the prevailing market condition is not good, in order to reduce the consumption of funds, the main funds can only choose to buy the stock and pull the stock up.
2. Stock status: the day the stock amplitude is large, the highest increase reached 9.99%, near the end of the day, the stock price quickly pulled up, there is a straight line sealing the single situation, the main force of funds in the pro-closing before the concentration of buying, may be in order to seal the stock price stop, so as to attract the attention of investors, attracting retail investors to buy, and to facilitate the main next day, the high opening out of the goods.
3. Chip distribution: the main funds have collected a large number of chips before, in the main funds to collect enough chips, the stock price in the end of the day to pull up, may be the main funds in order to impact the opening price on the next day and the operation.
China Pharmaceuticals stock for why not rise it
Multifaceted reasons for the combination of the role of the stock price delayed.
___The company's market capitalization is small and its performance is meager. The stock has a total share capital of 364 million, 153 million shares outstanding, earnings per share of 0.09 yuan, the domestic market demand for new crown medicine is low.
__ Secondly, the company's core products failed to appear on the list of generic versions of Chikintosu approved by the State Drug Administration and failed to respond to the exchange in a timely manner when questioned, resulting in the stock being stacked with penalties.
__ Again, the company previously announced that it would launch an employee stock ownership plan, but key elements such as specific sources of funds, the size of the funds, and assessment criteria were not specified in the implementation rules.
___Finally, the company has seen large personnel changes, a large number of shareholders and waning investor interest in its major product lines, such as milligrams of phenolic acid and macrolides.
The above combination of factors has led to a delayed rise in China Pharma's share price.
That's all for the introduction of why China's pharmaceutical stocks are soaring.